GH Research (GHRS) Income from Continuing Operations (2020 - 2025)
GH Research's (GHRS) quarterly Income from Continuing Operations came in at 13479000.0 in Q4 2025, down 22.21% year-on-year from 17328347.24 in Q4 2024, and up 3.86% quarter-over-quarter from 14020000.0 in Q3 2025.
GH Research (GHRS) Income from Continuing Operations (2020 - 2025) Analysis & Trends
GH Research's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 13479000.0 for Q4 2025.
- On a quarterly basis, Income from Continuing Operations fell 22.21% year-over-year to 13479000.0 in Q4 2025; TTM through Dec 2025 was 47600000.0, a 15.57% decrease from a year earlier, with the FY2025 full-year figure at 47600000.0, down 15.57% from the prior year.
- Income from Continuing Operations rose to 13479000.0 in Q4 2025 per GHRS's latest filing, from 14020000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 334000.0 in Q2 2022 and bottomed at 16586000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 8284000.0 (2023), against an average of 7680000.0.
- Across the five-year window, Income from Continuing Operations tumbled 2961.67% in 2021 and surged 115.72% in 2022, its largest moves.
- Year by year, Income from Continuing Operations stood at 4091000.0 in 2021, then sank by 305.43% to 16586000.0 in 2022, then surged by 46.71% to 8839000.0 in 2023, then dropped by 24.78% to 11029000.0 in 2024, then slipped by 22.21% to 13479000.0 in 2025.
- Per Business Quant, the three latest GHRS Income from Continuing Operations figures stand at 13479000.0 (Q4 2025), 14020000.0 (Q3 2025), and 9289000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | GH Research | 1.65 Bn | 1.65 Bn | - | -13.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13.48 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -9.29 Mn |
| Mar 31, 2025 | -10.81 Mn |
| Dec 31, 2024 | -11.03 Mn |
| Sep 30, 2024 | -12.11 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -7.67 Mn |
| Dec 31, 2023 | -8.84 Mn |
| Sep 30, 2023 | -5.65 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -10.94 Mn |
| Dec 31, 2022 | -16.59 Mn |
| Sep 30, 2022 | -441,000.00 |
| Jun 30, 2022 | 334,000.00 |
| Mar 31, 2022 | -5.76 Mn |
| Dec 31, 2021 | -4.09 Mn |
| Sep 30, 2021 | -1.84 Mn |
| Jun 30, 2021 | -2.13 Mn |
| Mar 31, 2021 | -1.15 Mn |